Please login to the form below

Not currently logged in
Email:
Password:

TT701

This page shows the latest TT701 news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

The big pharma company pockets just $1m upfront from the deal, although Transition could pay up to $100m in milestones if the small-molecule drug - called TT701 - eventually reaches the market. ... TT701 is a selective androgen receptor modulator (SARM)

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Transition Therapeutics with the out-licence of the phase II ready selective androgen receptor modulator TT701 to Transition. ... 105.5. Eli Lilly/ Transition Therapeutics. Licence agreement. For TT701 a selective androgen receptor modulator in P2 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics